The Utility of Molecular Imaging for Investigating Patients with Visual Hallucinations

References

1. 1.↵
   2. Winton-Brown TT,
   3. Ting A,
   4. Mocellin R, et al

   . Distinguishing neuroimaging features in patients presenting with visual hallucinations. AJNR Am J Neuroradiol 2016;37:774–81 doi:10.3174/ajnr.A4636 pmid:26744445

   Abstract/FREE Full Text
2. 2.↵
   2. McKeith I,
   3. O'Brien J,
   4. Walker Z, et al

   ; DLB Study Group. Sensitivity and specificity of dopamine transporter imaging with ¹²³I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305–13 doi:10.1016/S1474-4422(07)70057-1 pmid:17362834

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Brown KJ,
   3. Bohnen NI,
   4. Wong KK, et al

   . Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics 2014;34:684–701 doi:10.1148/rg.343135065 pmid:24819789

   CrossRefPubMed
4. 4.↵
   2. Ishii K

   . PET approaches for diagnosis of dementia. AJNR Am J Neuroradiol 2014;35:2030–38 doi:10.3174/ajnr.A3695 pmid:23945233

   Abstract/FREE Full Text